Literature DB >> 25902036

Large animal and primate models of spinal cord injury for the testing of novel therapies.

Brian K Kwon1, Femke Streijger2, Caitlin E Hill3, Aileen J Anderson4, Mark Bacon5, Michael S Beattie6, Armin Blesch7, Elizabeth J Bradbury8, Arthur Brown9, Jacqueline C Bresnahan10, Casey C Case11, Raymond W Colburn12, Samuel David13, James W Fawcett14, Adam R Ferguson15, Itzhak Fischer16, Candace L Floyd17, John C Gensel18, John D Houle19, Lyn B Jakeman20, Nick D Jeffery21, Linda Ann Truett Jones22, Naomi Kleitman23, Jeffery Kocsis24, Paul Lu25, David S K Magnuson26, Martin Marsala27, Simon W Moore28, Andrea J Mothe29, Martin Oudega30, Giles W Plant31, Alexander Sasha Rabchevsky32, Jan M Schwab33, Jerry Silver34, Oswald Steward35, Xiao-Ming Xu36, James D Guest37, Wolfram Tetzlaff38.   

Abstract

Large animal and primate models of spinal cord injury (SCI) are being increasingly utilized for the testing of novel therapies. While these represent intermediary animal species between rodents and humans and offer the opportunity to pose unique research questions prior to clinical trials, the role that such large animal and primate models should play in the translational pipeline is unclear. In this initiative we engaged members of the SCI research community in a questionnaire and round-table focus group discussion around the use of such models. Forty-one SCI researchers from academia, industry, and granting agencies were asked to complete a questionnaire about their opinion regarding the use of large animal and primate models in the context of testing novel therapeutics. The questions centered around how large animal and primate models of SCI would be best utilized in the spectrum of preclinical testing, and how much testing in rodent models was warranted before employing these models. Further questions were posed at a focus group meeting attended by the respondents. The group generally felt that large animal and primate models of SCI serve a potentially useful role in the translational pipeline for novel therapies, and that the rational use of these models would depend on the type of therapy and specific research question being addressed. While testing within these models should not be mandatory, the detection of beneficial effects using these models lends additional support for translating a therapy to humans. These models provides an opportunity to evaluate and refine surgical procedures prior to use in humans, and safety and bio-distribution in a spinal cord more similar in size and anatomy to that of humans. Our results reveal that while many feel that these models are valuable in the testing of novel therapies, important questions remain unanswered about how they should be used and how data derived from them should be interpreted.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cellular therapies; Drug therapies; Large animal models; Primate models; Questionnaire; Translation

Mesh:

Year:  2015        PMID: 25902036     DOI: 10.1016/j.expneurol.2015.04.008

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  29 in total

1.  CCL-2 as a possible early marker for remission after traumatic spinal cord injury.

Authors:  R A Heller; T F Raven; T Swing; K Kunzmann; V Daniel; P Haubruck; M Akbar; P A Grützner; G Schmidmaier; B Biglari; A Moghaddam
Journal:  Spinal Cord       Date:  2017-06-20       Impact factor: 2.772

Review 2.  CNS repair and axon regeneration: Using genetic variation to determine mechanisms.

Authors:  Andrea Tedeschi; Takao Omura; Michael Costigan
Journal:  Exp Neurol       Date:  2016-05-06       Impact factor: 5.330

3.  Independent replication of motor cortex and cervical spinal cord electrical stimulation to promote forelimb motor function after spinal cord injury in rats.

Authors:  Qi Yang; Aditya Ramamurthy; Sophia Lall; Joshua Santos; Shivakeshavan Ratnadurai-Giridharan; Madeleine Lopane; Neela Zareen; Heather Alexander; Daniel Ryan; John H Martin; Jason B Carmel
Journal:  Exp Neurol       Date:  2019-05-21       Impact factor: 5.330

Review 4.  Assessments of sensory plasticity after spinal cord injury across species.

Authors:  Jenny Haefeli; J Russell Huie; Kazuhito Morioka; Adam R Ferguson
Journal:  Neurosci Lett       Date:  2016-12-19       Impact factor: 3.046

5.  sCD95L in serum after spinal cord injury.

Authors:  A Moghaddam; A Sperl; R Heller; H J Gerner; B Biglari
Journal:  Spinal Cord       Date:  2016-04-19       Impact factor: 2.772

Review 6.  Urological Sequelae to Acute Spinal Cord Injury in Pet Dogs: A Natural Disease Model of Neuropathic Bladder Dysfunction.

Authors:  Laurie Cook; Julie Byron; Sarah Moore
Journal:  Top Spinal Cord Inj Rehabil       Date:  2019

7.  Restorative effects of human neural stem cell grafts on the primate spinal cord.

Authors:  Ephron S Rosenzweig; John H Brock; Paul Lu; Hiromi Kumamaru; Ernesto A Salegio; Ken Kadoya; Janet L Weber; Justine J Liang; Rod Moseanko; Stephanie Hawbecker; J Russell Huie; Leif A Havton; Yvette S Nout-Lomas; Adam R Ferguson; Michael S Beattie; Jacqueline C Bresnahan; Mark H Tuszynski
Journal:  Nat Med       Date:  2018-02-26       Impact factor: 53.440

8.  Exploratory study to suggest the possibility of MMP-8 and MMP-9 serum levels as early markers for remission after traumatic spinal cord injury.

Authors:  A Moghaddam; R Heller; V Daniel; T Swing; M Akbar; H-J Gerner; B Biglari
Journal:  Spinal Cord       Date:  2016-07-05       Impact factor: 2.772

9.  Mechanical Design and Analysis of a Unilateral Cervical Spinal Cord Contusion Injury Model in Non-Human Primates.

Authors:  Carolyn J Sparrey; Ernesto A Salegio; William Camisa; Horace Tam; Michael S Beattie; Jacqueline C Bresnahan
Journal:  J Neurotrauma       Date:  2016-04-19       Impact factor: 5.269

Review 10.  Drug delivery, cell-based therapies, and tissue engineering approaches for spinal cord injury.

Authors:  Shushi Kabu; Yue Gao; Brian K Kwon; Vinod Labhasetwar
Journal:  J Control Release       Date:  2015-09-04       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.